162 related articles for article (PubMed ID: 36715178)
21. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort.
Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E
Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078
[TBL] [Abstract][Full Text] [Related]
23. R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.
Matull WR; Dhar DK; Ayaru L; Sandanayake NS; Chapman MH; Dias A; Bridgewater J; Webster GJ; Bong JJ; Davidson BR; Pereira SP
Liver Int; 2011 Jan; 31(1):99-107. PubMed ID: 20846273
[TBL] [Abstract][Full Text] [Related]
24. Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015.
Koshiol J; Yu B; Kabadi SM; Baria K; Shroff RT
BMC Cancer; 2022 Nov; 22(1):1178. PubMed ID: 36384474
[TBL] [Abstract][Full Text] [Related]
25. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
27. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
28. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Mayr C; Kiesslich T; Modest DP; Stintzing S; Ocker M; Neureiter D
Expert Opin Investig Drugs; 2022 Feb; 31(2):221-233. PubMed ID: 35098846
[TBL] [Abstract][Full Text] [Related]
29. Advances in immunotherapy for biliary tract cancers.
Zhao Y; Yang M; Feng J; Wang X; Liu Y
Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
[TBL] [Abstract][Full Text] [Related]
30. Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Roth GS; Verlingue L; Sarabi M; Blanc JF; Boleslawski E; Boudjema K; Bretagne-Bignon AL; Camus-Duboc M; Coriat R; Créhange G; De Baere T; de la Fouchardière C; Dromain C; Edeline J; Gelli M; Guiu B; Horn S; Laurent-Croise V; Lepage C; Lièvre A; Lopez A; Manfredi S; Meilleroux J; Neuzillet C; Paradis V; Prat F; Ronot M; Rosmorduc O; Cunha AS; Soubrane O; Turpin A; Louvet C; Bouché O; Malka D
Eur J Cancer; 2024 May; 202():114000. PubMed ID: 38493667
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
32. Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort.
Liao SF; Koshiol J; Huang YH; Jackson SS; Huang YH; Chan C; Huang C; Liu PC; Chen YJ; Hsieh RJ; Huang CP; Lu SN; Chen CJ; Shen CY; Lee MH
Hepatology; 2021 Oct; 74(4):1994-2006. PubMed ID: 33942350
[TBL] [Abstract][Full Text] [Related]
33. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
Goeppert B; Folseraas T; Roessler S; Kloor M; Volckmar AL; Endris V; Buchhalter I; Stenzinger A; Grzyb K; Grimsrud MM; Gornicka B; von Seth E; Reynolds GM; Franke A; Gotthardt DN; Mehrabi A; Cheung A; Verheij J; Arola J; Mäkisalo H; Eide TJ; Weidemann S; Cheville JC; Mazza G; Hirschfield GM; Ponsioen CY; Bergquist A; Milkiewicz P; Lazaridis KN; Schramm C; Manns MP; Färkkilä M; Vogel A; ; Boberg KM; Schirmacher P; Karlsen TH
Hepatology; 2020 Oct; 72(4):1253-1266. PubMed ID: 31925805
[TBL] [Abstract][Full Text] [Related]
34. Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients.
Frega G; Garajová I; Palloni A; Barbera MA; Trossello Pastore M; Faccioli L; Spinardi L; De Lorenzo S; Cubelli M; Pantaleo MA; Biasco G; Brandi G
Oncology; 2018; 94(1):7-11. PubMed ID: 29024931
[TBL] [Abstract][Full Text] [Related]
35. Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer.
Harder J; Müller MJ; Fuchs M; Gumpp V; Schmitt-Graeff A; Fischer R; Frank M; Opitz O; Hasskarl J
World J Gastroenterol; 2013 Dec; 19(48):9334-42. PubMed ID: 24409060
[TBL] [Abstract][Full Text] [Related]
36. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
[No Abstract] [Full Text] [Related]
37. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
38. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Itano O; Takemura Y; Kishida N; Tamagawa E; Shinozaki H; Ikeda K; Urakami H; Ei S; Hayatsu S; Suzuki K; Sakuragawa T; Ishii M; Shito M; Aiura K; Fujisaki H; Takano K; Matsui J; Minagawa T; Shinoda M; Kitago M; Abe Y; Yagi H; Oshima G; Hori S; Kitagawa Y
BMC Cancer; 2020 Jul; 20(1):688. PubMed ID: 32703191
[TBL] [Abstract][Full Text] [Related]
39. Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
Cosgrove DP; Reese ES; Fulcher NM; Bobiak SS; Lamy FX; Allignol A; Boyd M; Mahmoudpour SH
Cancer Med; 2023 Feb; 12(4):4195-4205. PubMed ID: 36263922
[TBL] [Abstract][Full Text] [Related]
40. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.
Lee S; Shroff RT; Makawita S; Xiao L; Danner De Armas A; Bhosale P; Reddy K; Shalaby A; Raghav K; Pant S; Wolff RA; Javle M
Clin Cancer Res; 2022 Jun; 28(11):2229-2236. PubMed ID: 35312753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
